NCT01928394 · FLOW
Participant flow
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- groups
- description
- Triple Negative Breast Cancer (TNBC) Nivolumab monotherapy (3 mg/kg) Q2W
- id
- FG000
- title
- TNBC Arm N
- description
- Triple Negative Breast Cancer (TNBC) Nivolumab (1 mg/kg) + ipilimumab (1 mg/kg) Q3W for 4 doses, then nivolumab (3 mg/kg) Q2W
- id
- FG001
- title
- TNBC Arm N-I Dose Level 1
- description
- Triple Negative Breast Cancer (TNBC) Nivolumab (1 mg/kg) + ipilimumab (3 mg/kg) Q3W for 4 doses, then nivolumab (3 mg/kg) Q2W
- id
- FG002
- title
- TNBC Arm N-I Dose Level 2
- description
- Gastric Cancer (GC) Nivolumab 3 mg/kg Q2W
- id
- FG003
- title
- GC Arm N
- description
- Gastric Cancer(GC) Nivolumab (1 mg/kg) + ipilimumab (1 mg/kg) Q3W for 4 doses, then nivolumab (3 mg/kg) Q2W
- id
- FG004
- title
- GC Arm N-I Dose Level 1
- description
- Gastric Cancer (GC) nivolumab (1 mg/kg) + ipilimumab (3 mg/kg) Q3W for 4 doses; then nivolumab 3 mg/kg Q2W
- id
- FG005
- title
- GC Arm N-I Dose Level 2
- description
- Gastric Cancer (GC) Nivolumab 3 mg/kg + Ipilimumab 1 mg/kg Q3W for 4 doses, then Nivolumab (3 mg/kg) Q2W
- id
- FG006
- title
- GC Arm N-I Dose Level 2b
- description
- Pancreatic cancer (PC) participants: Nivolumab 3 mg/kg Q2W
- id
- FG007
- title
- PC Arm N
- description
- Pancreatic cancer (PC) participants: Nivolumab 1 mg/kg + Ipilimumab 1 mg/kg Q3W for 4 doses, then Nivolumab (3 mg/kg) Q2W
- id
- FG008
- title
- PC Arm N-I Dose Level 1
- description
- Pancreatic cancer (PC) participants: Nivolumab 1 mg/kg + Ipilimumab 3 mg/kg Q3W for 4 doses, then Nivolumab (3 mg/kg) Q2W
- id
- FG009
- title
- PC Arm N-I Dose Level 2
- description
- Pancreatic cancer (PC) participants: Nivolumab 3 mg/kg + Ipilimumab 1 mg/kg Q6W for 4 doses + cobimetinib 60 mg po qd 21 days on/7 days off
- id
- FG010
- title
- PC Arm N-I Dose Level 2d
- description
- Small cell lung cancer (SCLC) participants treated in Pre-expansion Cohort with Nivolumab 3 mg/kg Q2W
- id
- FG011
- title
- SCLC Arm N - Pre-expansion
- periods
- drop Withdraws
- reasons
- group Id
- FG000
- num Subjects
- 17
- group Id
- FG001
- num Subjects
- 2
- group Id
- FG002
- num Subjects
- 12
- group Id
- FG003
- num Subjects
- 48
- group Id
- FG004
- num Subjects
- 3
- group Id
- FG005
- num Subjects
- 25
- group Id
- FG006
- num Subjects
- 38
- group Id
- FG007
- num Subjects
- 16
- group Id
- FG008
- num Subjects
- 3
- group Id
- FG009
- num Subjects
- 11
- group Id
- FG010
- num Subjects
- 22
- group Id
- FG011
- num Subjects
- 73
- type
- Disease progression
- reasons
- group Id
- FG000
- num Subjects
- 1
- group Id
- FG001
- num Subjects
- 1
- group Id
- FG002
- num Subjects
- 3
- group Id
- FG003
- num Subjects
- 3
- group Id
- FG004
- num Subjects
- 0
- group Id
- FG005
- num Subjects
- 9
- group Id
- FG006
- num Subjects
- 7
- group Id
- FG007
- num Subjects
- 1
- group Id
- FG008
- num Subjects
- 0
- group Id
- FG009
- num Subjects
- 5
- group Id
- FG010
- num Subjects
- 2
- group Id
- FG011
- num Subjects
- 3
- type
- Study drug toxicity
- reasons
- group Id
- FG000
- num Subjects
- 0
- group Id
- FG001
- num Subjects
- 0
- group Id
- FG002
- num Subjects
- 2
- group Id
- FG003
- num Subjects
- 3
- group Id
- FG004
- num Subjects
- 0
- group Id
- FG005
- num Subjects
- 5
- group Id
- FG006
- num Subjects
- 1
- group Id
- FG007
- num Subjects
- 0
- group Id
- FG008
- num Subjects
- 0
- group Id
- FG009
- num Subjects
- 2
- group Id
- FG010
- num Subjects
- 0
- group Id
- FG011
- num Subjects
- 12
- type
- AE unrelated to study drug
- reasons
- group Id
- FG000
- num Subjects
- 0
- group Id
- FG001
- num Subjects
- 0
- group Id
- FG002
- num Subjects
- 0
- group Id
- FG003
- num Subjects
- 0
- group Id
- FG004
- num Subjects
- 0
- group Id
- FG005
- num Subjects
- 3
- group Id
- FG006
- num Subjects
- 3
- group Id
- FG007
- num Subjects
- 0
- group Id
- FG008
- num Subjects
- 0
- group Id
- FG009
- num Subjects
- 0
- group Id
- FG010
- num Subjects
- 3
- group Id
- FG011
- num Subjects
- 2
- type
- Participant request to stop therapy
- reasons
- group Id
- FG000
- num Subjects
- 0
- group Id
- FG001
- num Subjects
- 0
- group Id
- FG002
- num Subjects
- 1
- group Id
- FG003
- num Subjects
- 1
- group Id
- FG004
- num Subjects
- 0
- group Id
- FG005
- num Subjects
- 1
- group Id
- FG006
- num Subjects
- 0
- group Id
- FG007
- num Subjects
- 1
- group Id
- FG008
- num Subjects
- 0
- group Id
- FG009
- num Subjects
- 0
- group Id
- FG010
- num Subjects
- 1
- group Id
- FG011
- num Subjects
- 1
- type
- Participant withdrew consent
- reasons
- group Id
- FG000
- num Subjects
- 0
- group Id
- FG001
- num Subjects
- 0
- group Id
- FG002
- num Subjects
- 0
- group Id
- FG003
- num Subjects
- 1
- group Id
- FG004
- num Subjects
- 0
- group Id
- FG005
- num Subjects
- 0
- group Id
- FG006
- num Subjects
- 0
- group Id
- FG007
- num Subjects
- 0
- group Id
- FG008
- num Subjects
- 0
- group Id
- FG009
- num Subjects
- 0
- group Id
- FG010
- num Subjects
- 0
- group Id
- FG011
- num Subjects
- 0
- type
- Poor/non-compliance
- reasons
- group Id
- FG000
- num Subjects
- 0
- group Id
- FG001
- num Subjects
- 0
- group Id
- FG002
- num Subjects
- 0
- group Id
- FG003
- num Subjects
- 0
- group Id
- FG004
- num Subjects
- 0
- group Id
- FG005
- num Subjects
- 0
- group Id
- FG006
- num Subjects
- 0
- group Id
- FG007
- num Subjects
- 0
- group Id
- FG008
- num Subjects
- 0
- group Id
- FG009
- num Subjects
- 0
- group Id
- FG010
- num Subjects
- 1
- group Id
- FG011
- num Subjects
- 1
- type
- other reason
- reasons
- group Id
- FG000
- num Subjects
- 0
- group Id
- FG001
- num Subjects
- 0
- group Id
- FG002
- num Subjects
- 0
- group Id
- FG003
- num Subjects
- 0
- group Id
- FG004
- num Subjects
- 0
- group Id
- FG005
- num Subjects
- 0
- group Id
- FG006
- num Subjects
- 0
- group Id
- FG007
- num Subjects
- 0
- group Id
- FG008
- num Subjects
- 0
- group Id
- FG009
- num Subjects
- 0
- group Id
- FG010
- num Subjects
- 1
- group Id
- FG011
- num Subjects
- 1
- type
- Maximum clinical benefit
- reasons
- group Id
- FG000
- num Subjects
- 0
- group Id
- FG001
- num Subjects
- 0
- group Id
- FG002
- num Subjects
- 0
- group Id
- FG003
- num Subjects
- 0
- group Id
- FG004
- num Subjects
- 0
- group Id
- FG005
- num Subjects
- 0
- group Id
- FG006
- num Subjects
- 0
- group Id
- FG007
- num Subjects
- 0
- group Id
- FG008
- num Subjects
- 0
- group Id
- FG009
- num Subjects
- 0
- group Id
- FG010
- num Subjects
- 0
- group Id
- FG011
- num Subjects
- 0
- type
- Lost to Follow-up
- reasons
- group Id
- FG000
- num Subjects
- 0
- group Id
- FG001
- num Subjects
- 0
- group Id
- FG002
- num Subjects
- 0
- group Id
- FG003
- num Subjects
- 0
- group Id
- FG004
- num Subjects
- 0
- group Id
- FG005
- num Subjects
- 0
- group Id
- FG006
- num Subjects
- 0
- group Id
- FG007
- num Subjects
- 0
- group Id
- FG008
- num Subjects
- 0
- group Id
- FG009
- num Subjects
- 0
- group Id
- FG010
- num Subjects
- 0
- group Id
- FG011
- num Subjects
- 0
- type
- Death
- milestones
- achievements
- group Id
- FG000
- num Subjects
- 18
- group Id
- FG001
- num Subjects
- 3
- group Id
- FG002
- num Subjects
- 18
- group Id
- FG003
- num Subjects
- 59
- group Id
- FG004
- num Subjects
- 3
- group Id
- FG005
- num Subjects
- 49
- group Id
- FG006
- num Subjects
- 52
- group Id
- FG007
- num Subjects
- 18
- group Id
- FG008
- num Subjects
- 3
- group Id
- FG009
- num Subjects
- 18
- group Id
- FG010
- num Subjects
- 30
- group Id
- FG011
- num Subjects
- 98
- comment
- Started = Entering initial treatment or combination treatment after completion of monotherapy(MT)
- type
- STARTED
- achievements
- group Id
- FG000
- num Subjects
- 3
- group Id
- FG001
- num Subjects
- 0
- group Id
- FG002
- num Subjects
- 0
- group Id
- FG003
- num Subjects
- 9
- group Id
- FG004
- num Subjects
- 0
- group Id
- FG005
- num Subjects
- 0
- group Id
- FG006
- num Subjects
- 0
- group Id
- FG007
- num Subjects
- 2
- group Id
- FG008
- num Subjects
- 0
- group Id
- FG009
- num Subjects
- 0
- group Id
- FG010
- num Subjects
- 0
- group Id
- FG011
- num Subjects
- 17
- comment
- Participants who will transition after completing MT due to disease progression (DP)
- type
- Transition
- achievements
- group Id
- FG000
- num Subjects
- 0
- group Id
- FG001
- num Subjects
- 0
- group Id
- FG002
- num Subjects
- 3
- group Id
- FG003
- num Subjects
- 0
- group Id
- FG004
- num Subjects
- 0
- group Id
- FG005
- num Subjects
- 3
- group Id
- FG006
- num Subjects
- 6
- group Id
- FG007
- num Subjects
- 0
- group Id
- FG008
- num Subjects
- 1
- group Id
- FG009
- num Subjects
- 1
- group Id
- FG010
- num Subjects
- 0
- group Id
- FG011
- num Subjects
- 0
- comment
- Participants who were transitioned to another treatment after disease progression (DP).
- type
- Transition- Continued
- achievements
- group Id
- FG000
- num Subjects
- 0
- group Id
- FG001
- num Subjects
- 0
- group Id
- FG002
- num Subjects
- 0
- group Id
- FG003
- num Subjects
- 3
- group Id
- FG004
- num Subjects
- 0
- group Id
- FG005
- num Subjects
- 6
- group Id
- FG006
- num Subjects
- 3
- group Id
- FG007
- num Subjects
- 0
- group Id
- FG008
- num Subjects
- 0
- group Id
- FG009
- num Subjects
- 0
- group Id
- FG010
- num Subjects
- 0
- group Id
- FG011
- num Subjects
- 5
- comment
- Completed = continuing treatment period
- type
- COMPLETED
- achievements
- group Id
- FG000
- num Subjects
- 18
- group Id
- FG001
- num Subjects
- 3
- group Id
- FG002
- num Subjects
- 18
- group Id
- FG003
- num Subjects
- 56
- group Id
- FG004
- num Subjects
- 3
- group Id
- FG005
- num Subjects
- 43
- group Id
- FG006
- num Subjects
- 49
- group Id
- FG007
- num Subjects
- 18
- group Id
- FG008
- num Subjects
- 3
- group Id
- FG009
- num Subjects
- 18
- group Id
- FG010
- num Subjects
- 30
- group Id
- FG011
- num Subjects
- 93
- type
- NOT COMPLETED
- title
- Treatment Period
- drop Withdraws
- reasons
- group Id
- FG000
- num Subjects
- 3
- group Id
- FG001
- num Subjects
- 0
- group Id
- FG002
- num Subjects
- 1
- group Id
- FG003
- num Subjects
- 4
- group Id
- FG004
- num Subjects
- 0
- group Id
- FG005
- num Subjects
- 2
- group Id
- FG006
- num Subjects
- 5
- group Id
- FG007
- num Subjects
- 1
- group Id
- FG008
- num Subjects
- 0
- group Id
- FG009
- num Subjects
- 0
- group Id
- FG010
- num Subjects
- 5
- group Id
- FG011
- num Subjects
- 8
- type
- Participant withdrew consent
- reasons
- group Id
- FG000
- num Subjects
- 0
- group Id
- FG001
- num Subjects
- 0
- group Id
- FG002
- num Subjects
- 2
- group Id
- FG003
- num Subjects
- 6
- group Id
- FG004
- num Subjects
- 0
- group Id
- FG005
- num Subjects
- 6
- group Id
- FG006
- num Subjects
- 6
- group Id
- FG007
- num Subjects
- 2
- group Id
- FG008
- num Subjects
- 1
- group Id
- FG009
- num Subjects
- 2
- group Id
- FG010
- num Subjects
- 4
- group Id
- FG011
- num Subjects
- 12
- type
- Death
- reasons
- group Id
- FG000
- num Subjects
- 0
- group Id
- FG001
- num Subjects
- 0
- group Id
- FG002
- num Subjects
- 0
- group Id
- FG003
- num Subjects
- 0
- group Id
- FG004
- num Subjects
- 0
- group Id
- FG005
- num Subjects
- 0
- group Id
- FG006
- num Subjects
- 1
- group Id
- FG007
- num Subjects
- 3
- group Id
- FG008
- num Subjects
- 0
- group Id
- FG009
- num Subjects
- 0
- group Id
- FG010
- num Subjects
- 2
- group Id
- FG011
- num Subjects
- 1
- type
- other reason
- reasons
- group Id
- FG000
- num Subjects
- 0
- group Id
- FG001
- num Subjects
- 0
- group Id
- FG002
- num Subjects
- 0
- group Id
- FG003
- num Subjects
- 0
- group Id
- FG004
- num Subjects
- 0
- group Id
- FG005
- num Subjects
- 0
- group Id
- FG006
- num Subjects
- 0
- group Id
- FG007
- num Subjects
- 0
- group Id
- FG008
- num Subjects
- 0
- group Id
- FG009
- num Subjects
- 0
- group Id
- FG010
- num Subjects
- 0
- group Id
- FG011
- num Subjects
- 1
- type
- Lost to Follow-up
- milestones
- achievements
- group Id
- FG000
- num Subjects
- 15
- group Id
- FG001
- num Subjects
- 3
- group Id
- FG002
- num Subjects
- 18
- group Id
- FG003
- num Subjects
- 50
- group Id
- FG004
- num Subjects
- 3
- group Id
- FG005
- num Subjects
- 49
- group Id
- FG006
- num Subjects
- 52
- group Id
- FG007
- num Subjects
- 16
- group Id
- FG008
- num Subjects
- 3
- group Id
- FG009
- num Subjects
- 18
- group Id
- FG010
- num Subjects
- 30
- group Id
- FG011
- num Subjects
- 81
- comment
- started = number of Participants regardless of continuing treatment or not.
- type
- STARTED
- achievements
- group Id
- FG000
- num Subjects
- 12
- group Id
- FG001
- num Subjects
- 3
- group Id
- FG002
- num Subjects
- 15
- group Id
- FG003
- num Subjects
- 40
- group Id
- FG004
- num Subjects
- 3
- group Id
- FG005
- num Subjects
- 41
- group Id
- FG006
- num Subjects
- 40
- group Id
- FG007
- num Subjects
- 10
- group Id
- FG008
- num Subjects
- 2
- group Id
- FG009
- num Subjects
- 16
- group Id
- FG010
- num Subjects
- 19
- group Id
- FG011
- num Subjects
- 59
- comment
- completed = continuing to be followed
- type
- COMPLETED
- achievements
- group Id
- FG000
- num Subjects
- 3
- group Id
- FG001
- num Subjects
- 0
- group Id
- FG002
- num Subjects
- 3
- group Id
- FG003
- num Subjects
- 10
- group Id
- FG004
- num Subjects
- 0
- group Id
- FG005
- num Subjects
- 8
- group Id
- FG006
- num Subjects
- 12
- group Id
- FG007
- num Subjects
- 6
- group Id
- FG008
- num Subjects
- 1
- group Id
- FG009
- num Subjects
- 2
- group Id
- FG010
- num Subjects
- 11
- group Id
- FG011
- num Subjects
- 22
- type
- NOT COMPLETED
- title
- Follow-up Period
- pre Assignment Details
- 1131 participants were treated in total for TNBC, GC, PC, SCLC, BC and OC.
Complete source fields
- groups
- description
- Triple Negative Breast Cancer (TNBC) Nivolumab monotherapy (3 mg/kg) Q2W
- id
- FG000
- title
- TNBC Arm N
- description
- Triple Negative Breast Cancer (TNBC) Nivolumab (1 mg/kg) + ipilimumab (1 mg/kg) Q3W for 4 doses, then nivolumab (3 mg/kg) Q2W
- id
- FG001
- title
- TNBC Arm N-I Dose Level 1
- description
- Triple Negative Breast Cancer (TNBC) Nivolumab (1 mg/kg) + ipilimumab (3 mg/kg) Q3W for 4 doses, then nivolumab (3 mg/kg) Q2W
- id
- FG002
- title
- TNBC Arm N-I Dose Level 2
- description
- Gastric Cancer (GC) Nivolumab 3 mg/kg Q2W
- id
- FG003
- title
- GC Arm N
- description
- Gastric Cancer(GC) Nivolumab (1 mg/kg) + ipilimumab (1 mg/kg) Q3W for 4 doses, then nivolumab (3 mg/kg) Q2W
- id
- FG004
- title
- GC Arm N-I Dose Level 1
- description
- Gastric Cancer (GC) nivolumab (1 mg/kg) + ipilimumab (3 mg/kg) Q3W for 4 doses; then nivolumab 3 mg/kg Q2W
- id
- FG005
- title
- GC Arm N-I Dose Level 2
- description
- Gastric Cancer (GC) Nivolumab 3 mg/kg + Ipilimumab 1 mg/kg Q3W for 4 doses, then Nivolumab (3 mg/kg) Q2W
- id
- FG006
- title
- GC Arm N-I Dose Level 2b
- description
- Pancreatic cancer (PC) participants: Nivolumab 3 mg/kg Q2W
- id
- FG007
- title
- PC Arm N
- description
- Pancreatic cancer (PC) participants: Nivolumab 1 mg/kg + Ipilimumab 1 mg/kg Q3W for 4 doses, then Nivolumab (3 mg/kg) Q2W
- id
- FG008
- title
- PC Arm N-I Dose Level 1
- description
- Pancreatic cancer (PC) participants: Nivolumab 1 mg/kg + Ipilimumab 3 mg/kg Q3W for 4 doses, then Nivolumab (3 mg/kg) Q2W
- id
- FG009
- title
- PC Arm N-I Dose Level 2
- description
- Pancreatic cancer (PC) participants: Nivolumab 3 mg/kg + Ipilimumab 1 mg/kg Q6W for 4 doses + cobimetinib 60 mg po qd 21 days on/7 days off
- id
- FG010
- title
- PC Arm N-I Dose Level 2d
- description
- Small cell lung cancer (SCLC) participants treated in Pre-expansion Cohort with Nivolumab 3 mg/kg Q2W
- id
- FG011
- title
- SCLC Arm N - Pre-expansion
- periods
- drop Withdraws
- reasons
- group Id
- FG000
- num Subjects
- 17
- group Id
- FG001
- num Subjects
- 2
- group Id
- FG002
- num Subjects
- 12
- group Id
- FG003
- num Subjects
- 48
- group Id
- FG004
- num Subjects
- 3
- group Id
- FG005
- num Subjects
- 25
- group Id
- FG006
- num Subjects
- 38
- group Id
- FG007
- num Subjects
- 16
- group Id
- FG008
- num Subjects
- 3
- group Id
- FG009
- num Subjects
- 11
- group Id
- FG010
- num Subjects
- 22
- group Id
- FG011
- num Subjects
- 73
- type
- Disease progression
- reasons
- group Id
- FG000
- num Subjects
- 1
- group Id
- FG001
- num Subjects
- 1
- group Id
- FG002
- num Subjects
- 3
- group Id
- FG003
- num Subjects
- 3
- group Id
- FG004
- num Subjects
- 0
- group Id
- FG005
- num Subjects
- 9
- group Id
- FG006
- num Subjects
- 7
- group Id
- FG007
- num Subjects
- 1
- group Id
- FG008
- num Subjects
- 0
- group Id
- FG009
- num Subjects
- 5
- group Id
- FG010
- num Subjects
- 2
- group Id
- FG011
- num Subjects
- 3
- type
- Study drug toxicity
- reasons
- group Id
- FG000
- num Subjects
- 0
- group Id
- FG001
- num Subjects
- 0
- group Id
- FG002
- num Subjects
- 2
- group Id
- FG003
- num Subjects
- 3
- group Id
- FG004
- num Subjects
- 0
- group Id
- FG005
- num Subjects
- 5
- group Id
- FG006
- num Subjects
- 1
- group Id
- FG007
- num Subjects
- 0
- group Id
- FG008
- num Subjects
- 0
- group Id
- FG009
- num Subjects
- 2
- group Id
- FG010
- num Subjects
- 0
- group Id
- FG011
- num Subjects
- 12
- type
- AE unrelated to study drug
- reasons
- group Id
- FG000
- num Subjects
- 0
- group Id
- FG001
- num Subjects
- 0
- group Id
- FG002
- num Subjects
- 0
- group Id
- FG003
- num Subjects
- 0
- group Id
- FG004
- num Subjects
- 0
- group Id
- FG005
- num Subjects
- 3
- group Id
- FG006
- num Subjects
- 3
- group Id
- FG007
- num Subjects
- 0
- group Id
- FG008
- num Subjects
- 0
- group Id
- FG009
- num Subjects
- 0
- group Id
- FG010
- num Subjects
- 3
- group Id
- FG011
- num Subjects
- 2
- type
- Participant request to stop therapy
- reasons
- group Id
- FG000
- num Subjects
- 0
- group Id
- FG001
- num Subjects
- 0
- group Id
- FG002
- num Subjects
- 1
- group Id
- FG003
- num Subjects
- 1
- group Id
- FG004
- num Subjects
- 0
- group Id
- FG005
- num Subjects
- 1
- group Id
- FG006
- num Subjects
- 0
- group Id
- FG007
- num Subjects
- 1
- group Id
- FG008
- num Subjects
- 0
- group Id
- FG009
- num Subjects
- 0
- group Id
- FG010
- num Subjects
- 1
- group Id
- FG011
- num Subjects
- 1
- type
- Participant withdrew consent
- reasons
- group Id
- FG000
- num Subjects
- 0
- group Id
- FG001
- num Subjects
- 0
- group Id
- FG002
- num Subjects
- 0
- group Id
- FG003
- num Subjects
- 1
- group Id
- FG004
- num Subjects
- 0
- group Id
- FG005
- num Subjects
- 0
- group Id
- FG006
- num Subjects
- 0
- group Id
- FG007
- num Subjects
- 0
- group Id
- FG008
- num Subjects
- 0
- group Id
- FG009
- num Subjects
- 0
- group Id
- FG010
- num Subjects
- 0
- group Id
- FG011
- num Subjects
- 0
- type
- Poor/non-compliance
- reasons
- group Id
- FG000
- num Subjects
- 0
- group Id
- FG001
- num Subjects
- 0
- group Id
- FG002
- num Subjects
- 0
- group Id
- FG003
- num Subjects
- 0
- group Id
- FG004
- num Subjects
- 0
- group Id
- FG005
- num Subjects
- 0
- group Id
- FG006
- num Subjects
- 0
- group Id
- FG007
- num Subjects
- 0
- group Id
- FG008
- num Subjects
- 0
- group Id
- FG009
- num Subjects
- 0
- group Id
- FG010
- num Subjects
- 1
- group Id
- FG011
- num Subjects
- 1
- type
- other reason
- reasons
- group Id
- FG000
- num Subjects
- 0
- group Id
- FG001
- num Subjects
- 0
- group Id
- FG002
- num Subjects
- 0
- group Id
- FG003
- num Subjects
- 0
- group Id
- FG004
- num Subjects
- 0
- group Id
- FG005
- num Subjects
- 0
- group Id
- FG006
- num Subjects
- 0
- group Id
- FG007
- num Subjects
- 0
- group Id
- FG008
- num Subjects
- 0
- group Id
- FG009
- num Subjects
- 0
- group Id
- FG010
- num Subjects
- 1
- group Id
- FG011
- num Subjects
- 1
- type
- Maximum clinical benefit
- reasons
- group Id
- FG000
- num Subjects
- 0
- group Id
- FG001
- num Subjects
- 0
- group Id
- FG002
- num Subjects
- 0
- group Id
- FG003
- num Subjects
- 0
- group Id
- FG004
- num Subjects
- 0
- group Id
- FG005
- num Subjects
- 0
- group Id
- FG006
- num Subjects
- 0
- group Id
- FG007
- num Subjects
- 0
- group Id
- FG008
- num Subjects
- 0
- group Id
- FG009
- num Subjects
- 0
- group Id
- FG010
- num Subjects
- 0
- group Id
- FG011
- num Subjects
- 0
- type
- Lost to Follow-up
- reasons
- group Id
- FG000
- num Subjects
- 0
- group Id
- FG001
- num Subjects
- 0
- group Id
- FG002
- num Subjects
- 0
- group Id
- FG003
- num Subjects
- 0
- group Id
- FG004
- num Subjects
- 0
- group Id
- FG005
- num Subjects
- 0
- group Id
- FG006
- num Subjects
- 0
- group Id
- FG007
- num Subjects
- 0
- group Id
- FG008
- num Subjects
- 0
- group Id
- FG009
- num Subjects
- 0
- group Id
- FG010
- num Subjects
- 0
- group Id
- FG011
- num Subjects
- 0
- type
- Death
- milestones
- achievements
- group Id
- FG000
- num Subjects
- 18
- group Id
- FG001
- num Subjects
- 3
- group Id
- FG002
- num Subjects
- 18
- group Id
- FG003
- num Subjects
- 59
- group Id
- FG004
- num Subjects
- 3
- group Id
- FG005
- num Subjects
- 49
- group Id
- FG006
- num Subjects
- 52
- group Id
- FG007
- num Subjects
- 18
- group Id
- FG008
- num Subjects
- 3
- group Id
- FG009
- num Subjects
- 18
- group Id
- FG010
- num Subjects
- 30
- group Id
- FG011
- num Subjects
- 98
- comment
- Started = Entering initial treatment or combination treatment after completion of monotherapy(MT)
- type
- STARTED
- achievements
- group Id
- FG000
- num Subjects
- 3
- group Id
- FG001
- num Subjects
- 0
- group Id
- FG002
- num Subjects
- 0
- group Id
- FG003
- num Subjects
- 9
- group Id
- FG004
- num Subjects
- 0
- group Id
- FG005
- num Subjects
- 0
- group Id
- FG006
- num Subjects
- 0
- group Id
- FG007
- num Subjects
- 2
- group Id
- FG008
- num Subjects
- 0
- group Id
- FG009
- num Subjects
- 0
- group Id
- FG010
- num Subjects
- 0
- group Id
- FG011
- num Subjects
- 17
- comment
- Participants who will transition after completing MT due to disease progression (DP)
- type
- Transition
- achievements
- group Id
- FG000
- num Subjects
- 0
- group Id
- FG001
- num Subjects
- 0
- group Id
- FG002
- num Subjects
- 3
- group Id
- FG003
- num Subjects
- 0
- group Id
- FG004
- num Subjects
- 0
- group Id
- FG005
- num Subjects
- 3
- group Id
- FG006
- num Subjects
- 6
- group Id
- FG007
- num Subjects
- 0
- group Id
- FG008
- num Subjects
- 1
- group Id
- FG009
- num Subjects
- 1
- group Id
- FG010
- num Subjects
- 0
- group Id
- FG011
- num Subjects
- 0
- comment
- Participants who were transitioned to another treatment after disease progression (DP).
- type
- Transition- Continued
- achievements
- group Id
- FG000
- num Subjects
- 0
- group Id
- FG001
- num Subjects
- 0
- group Id
- FG002
- num Subjects
- 0
- group Id
- FG003
- num Subjects
- 3
- group Id
- FG004
- num Subjects
- 0
- group Id
- FG005
- num Subjects
- 6
- group Id
- FG006
- num Subjects
- 3
- group Id
- FG007
- num Subjects
- 0
- group Id
- FG008
- num Subjects
- 0
- group Id
- FG009
- num Subjects
- 0
- group Id
- FG010
- num Subjects
- 0
- group Id
- FG011
- num Subjects
- 5
- comment
- Completed = continuing treatment period
- type
- COMPLETED
- achievements
- group Id
- FG000
- num Subjects
- 18
- group Id
- FG001
- num Subjects
- 3
- group Id
- FG002
- num Subjects
- 18
- group Id
- FG003
- num Subjects
- 56
- group Id
- FG004
- num Subjects
- 3
- group Id
- FG005
- num Subjects
- 43
- group Id
- FG006
- num Subjects
- 49
- group Id
- FG007
- num Subjects
- 18
- group Id
- FG008
- num Subjects
- 3
- group Id
- FG009
- num Subjects
- 18
- group Id
- FG010
- num Subjects
- 30
- group Id
- FG011
- num Subjects
- 93
- type
- NOT COMPLETED
- title
- Treatment Period
- drop Withdraws
- reasons
- group Id
- FG000
- num Subjects
- 3
- group Id
- FG001
- num Subjects
- 0
- group Id
- FG002
- num Subjects
- 1
- group Id
- FG003
- num Subjects
- 4
- group Id
- FG004
- num Subjects
- 0
- group Id
- FG005
- num Subjects
- 2
- group Id
- FG006
- num Subjects
- 5
- group Id
- FG007
- num Subjects
- 1
- group Id
- FG008
- num Subjects
- 0
- group Id
- FG009
- num Subjects
- 0
- group Id
- FG010
- num Subjects
- 5
- group Id
- FG011
- num Subjects
- 8
- type
- Participant withdrew consent
- reasons
- group Id
- FG000
- num Subjects
- 0
- group Id
- FG001
- num Subjects
- 0
- group Id
- FG002
- num Subjects
- 2
- group Id
- FG003
- num Subjects
- 6
- group Id
- FG004
- num Subjects
- 0
- group Id
- FG005
- num Subjects
- 6
- group Id
- FG006
- num Subjects
- 6
- group Id
- FG007
- num Subjects
- 2
- group Id
- FG008
- num Subjects
- 1
- group Id
- FG009
- num Subjects
- 2
- group Id
- FG010
- num Subjects
- 4
- group Id
- FG011
- num Subjects
- 12
- type
- Death
- reasons
- group Id
- FG000
- num Subjects
- 0
- group Id
- FG001
- num Subjects
- 0
- group Id
- FG002
- num Subjects
- 0
- group Id
- FG003
- num Subjects
- 0
- group Id
- FG004
- num Subjects
- 0
- group Id
- FG005
- num Subjects
- 0
- group Id
- FG006
- num Subjects
- 1
- group Id
- FG007
- num Subjects
- 3
- group Id
- FG008
- num Subjects
- 0
- group Id
- FG009
- num Subjects
- 0
- group Id
- FG010
- num Subjects
- 2
- group Id
- FG011
- num Subjects
- 1
- type
- other reason
- reasons
- group Id
- FG000
- num Subjects
- 0
- group Id
- FG001
- num Subjects
- 0
- group Id
- FG002
- num Subjects
- 0
- group Id
- FG003
- num Subjects
- 0
- group Id
- FG004
- num Subjects
- 0
- group Id
- FG005
- num Subjects
- 0
- group Id
- FG006
- num Subjects
- 0
- group Id
- FG007
- num Subjects
- 0
- group Id
- FG008
- num Subjects
- 0
- group Id
- FG009
- num Subjects
- 0
- group Id
- FG010
- num Subjects
- 0
- group Id
- FG011
- num Subjects
- 1
- type
- Lost to Follow-up
- milestones
- achievements
- group Id
- FG000
- num Subjects
- 15
- group Id
- FG001
- num Subjects
- 3
- group Id
- FG002
- num Subjects
- 18
- group Id
- FG003
- num Subjects
- 50
- group Id
- FG004
- num Subjects
- 3
- group Id
- FG005
- num Subjects
- 49
- group Id
- FG006
- num Subjects
- 52
- group Id
- FG007
- num Subjects
- 16
- group Id
- FG008
- num Subjects
- 3
- group Id
- FG009
- num Subjects
- 18
- group Id
- FG010
- num Subjects
- 30
- group Id
- FG011
- num Subjects
- 81
- comment
- started = number of Participants regardless of continuing treatment or not.
- type
- STARTED
- achievements
- group Id
- FG000
- num Subjects
- 12
- group Id
- FG001
- num Subjects
- 3
- group Id
- FG002
- num Subjects
- 15
- group Id
- FG003
- num Subjects
- 40
- group Id
- FG004
- num Subjects
- 3
- group Id
- FG005
- num Subjects
- 41
- group Id
- FG006
- num Subjects
- 40
- group Id
- FG007
- num Subjects
- 10
- group Id
- FG008
- num Subjects
- 2
- group Id
- FG009
- num Subjects
- 16
- group Id
- FG010
- num Subjects
- 19
- group Id
- FG011
- num Subjects
- 59
- comment
- completed = continuing to be followed
- type
- COMPLETED
- achievements
- group Id
- FG000
- num Subjects
- 3
- group Id
- FG001
- num Subjects
- 0
- group Id
- FG002
- num Subjects
- 3
- group Id
- FG003
- num Subjects
- 10
- group Id
- FG004
- num Subjects
- 0
- group Id
- FG005
- num Subjects
- 8
- group Id
- FG006
- num Subjects
- 12
- group Id
- FG007
- num Subjects
- 6
- group Id
- FG008
- num Subjects
- 1
- group Id
- FG009
- num Subjects
- 2
- group Id
- FG010
- num Subjects
- 11
- group Id
- FG011
- num Subjects
- 22
- type
- NOT COMPLETED
- title
- Follow-up Period
- pre Assignment Details
- 1131 participants were treated in total for TNBC, GC, PC, SCLC, BC and OC.
Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0
Preserved source evidence · Not medical advice
Triangle